Sepsis is a frequent and life-threatening complication of microbial infections. It is estimated that more than 750,000 annual cases of sepsis occur in the United States and mortality rates remain around 20-50% despite recent advances of critical care support. In the current absence of FDA-approved pharmacologic compounds, there remains an urgent need for a complete characterization of the underlying cellular and molecular mechanisms of sepsis. The dysregulated host response is a prominent feature during the pathophysiology of bacterial sepsis, but the delicate balance of its integrating molecular pathways appear not entirely clear. Mitochondrial antiviral-signaling protein (MAVS) is an adaptor molecule in the outer mitochondrial membrane and is highly expressed in professional phagocytes. MAVS is activated by the cytoplasmic RNA helicases, RIG- I and MDA5, and confers protection against viral infections. Surprisingly, our preliminary findings suggest deletion of MAVS or RIG-I/MDA5 in mice confers immense resistance to mortality and modulates phagocyte transcriptomes, immunoproteasomes, extracellular traps, IL-6/IL-12 cytokines and blood coagulation during polymicrobial bacterial sepsis. Bacterial RNAs are a viability-associated pathogen patterns (`vita-PAMPs') sensed by the MAVS pathway in macrophages. Together, these findings suggest a detrimental role reversal of MAVS during bacterial sepsis as opposed to protective MAVS pathway functions during infections with viruses. To test our central hypothesis that MAVS signaling provides a lethal switch for obstructing favorable sepsis outcomes, we will pursue 3 specific aims: (1) We will study the gene expression, activation mechanisms, signaling events and functional roles of MAVS in professional phagocytes (macrophages, neutrophils) during polymicrobial bacterial sepsis. For these studies, mice with total or conditional gene deletion of MAVS, or the RIG-I/MDA5 sensors are available. MAVS-deficient human macrophages will be generated using CRISPR-Cas9. (2) We will determine how MAVS-induced transcription factors promote gene expression of immunoproteasome subunits, what the pleiotropic functions of the immunoproteasome are during bacterial sepsis, and how the immunoproteasome shapes the proteomes and transcriptomes of macrophages. These studies will include using triple-knockout mice for all three regulatory immunoproteasome subunits (PSMB8/9/10). (3) We will study how the MAVS pathway amplifies the harmful molecular sequelae of bacterial sepsis focusing on phagocyte extracellular traps (NETs/METs), IL-6/IL-12 cytokines, septic coagulopathy and immunosuppression; which all contribute to tissue injury, organ dysfunction and sepsis lethality. In particular, we will consider a novel role of the immunoproteasome in subcellular protein degradation for facilitating extracellular trap formation. In summary, elucidating the previously unsuspected involvement of the MAVS pathway during bacterial infection will provide novel and important information and may add critical insights for guiding future efforts to develop effective therapies for sepsis.

Public Health Relevance

Bacterial sepsis is among the leading causes of morbidity and mortality worldwide because of the absence of causal treatments. Here, we hypothesize that the antiviral mitochondrial signaling (MAVS) pathway is a critical switch activated by bacterial RNA, as viability-associated PAMPs, for disturbing delicate balances of immunoproteasomes, tissue injuring extracellular traps, IL-6/IL- 12 family cytokines and blood coagulation in bacterial sepsis. The proposed experimental studies will provide fundamental new insights in the molecular mechanisms of host response to severe infection for future exploitation as novel therapeutic interventions.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL141513-03
Application #
9944659
Study Section
Surgery, Anesthesiology and Trauma Study Section (SAT)
Program Officer
Rizwan, Asif M
Project Start
2018-08-15
Project End
2023-06-30
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
3
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Boston University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
604483045
City
Boston
State
MA
Country
United States
Zip Code
02118